4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
4D Molecular Therapeutics (Nasdaq: FDMT) said management will participate in panel discussions at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025.
Management will attend two panels: "In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications" at 9:30 a.m. ET and "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" at 2:00 p.m. ET. Webcasts are available, and archived copies will be posted for up to one year in the Investors section at https://ir.4dmoleculartherapeutics.com/events. Company representatives will also be available for one-on-one meetings.
4D Molecular Therapeutics (Nasdaq: FDMT) ha dichiarato che la dirigenza parteciperà a discussioni in panel alla 9ª Conferenza Annuale di Genetica Medica di Chardan il 21 ottobre 2025.
La dirigenza parteciperà a due panel: "In Vivo Gene Therapy: Break into Competitive Ophthalmic Indications" alle 9:30 a.m. ET e "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" alle 14:00 ET. Sono disponibili webcasts, e copie archiviate saranno pubblicate per un massimo di un anno nella sezione Investitori all'indirizzo https://ir.4dmoleculartherapeutics.com/events. I rappresentanti dell'azienda saranno inoltre disponibili per incontri one-to-one.
4D Molecular Therapeutics (Nasdaq: FDMT) declaró que la dirección participará en paneles de discusión en la 9ª Conferencia Anual de Medicinas Genéticas de Chardan el 21 de octubre de 2025.
La dirección asistirá a dos paneles: "In Vivo Gene Therapy: Break into Competitive Ophthalmic Indications" a las 9:30 a.m. ET y "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" a las 2:00 p.m. ET. Habrá webcasts disponibles, y las copias archivadas se publicarán durante un máximo de un año en la sección Inversores en https://ir.4dmoleculartherapeutics.com/events. Los representantes de la empresa también estarán disponibles para reuniones uno a uno.
4D Molecular Therapeutics (나스닥: FDMT)의 경영진은 Chardan의 제9회 연례 유전의학 컨퍼런스의 패널 토론에 참여할 예정이며 날짜는 2025년 10월 21일입니다.
경영진은 두 개의 패널에 참석합니다: "In Vivo Gene Therapy: Break into Competitive Ophthalmic Indications" 오전 9:30 ET와 "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" 오후 2:00 ET. 웹캐스트가 이용 가능하며 보관 사본은 최대 1년간 투자자 섹션의 https://ir.4dmoleculartherapeutics.com/events에 게시됩니다. 회사 대표는 1:1 미팅도 가능합니다.
4D Molecular Therapeutics (NASDAQ : FDMT) a annoncé que la direction participera à des tables rondes lors de la 9e Conférence annuelle sur les médicaments génétiques de Chardan le 21 octobre 2025.
La direction assistera à deux panels : "In Vivo Gene Therapy: Break into Competitive Ophthalmic Indications" à 9h30 ET et "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" à 14h ET. Des webcasts seront disponibles, et des copies archivées seront publiées jusqu'à un an dans la section Investisseurs sur https://ir.4dmoleculartherapeutics.com/events. Des représentants de l'entreprise seront également disponibles pour des réunions en tête-à-tête.
4D Molecular Therapeutics (Nasdaq: FDMT) teilte mit, dass das Management an Podiumsdiskussionen bei der Chardans neunter jährlicher Konferenz über genetische Medikamente am 21. Oktober 2025 teilnehmen wird.
Das Management wird an zwei Panels teilnehmen: "In Vivo Gene Therapy: Break into Competitive Ophthalmic Indications" um 9:30 Uhr EST und "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" um 14:00 Uhr EST. Webcasts sind verfügbar, archivierte Kopien werden bis zu einem Jahr im Bereich Investoren unter https://ir.4dmoleculartherapeutics.com/events veröffentlicht. Unternehmensvertreter stehen auch für 1-zu-1-Meetings zur Verfügung.
4D Molecular Therapeutics (ناسداك: FDMT) ذكرت الإدارة أنها ستشارك في نقاشات لجنة في المؤتمر التاسع للطب الجيني السنوي من تشاردان في 21 أكتوبر 2025.
سيحضر الإدارة جلستين: "In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications" في 9:30 صباحًا بتوقيت شرق الولايات المتحدة و "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" في 2:00 مساءً بتوقيت شرق الولايات المتحدة. هناك بثوث عبر الويب متاحة، ستُنشَر نسخ أرشيفية لمدة تصل إلى سنة في قسم المستثمرون على https://ir.4dmoleculartherapeutics.com/events. كما سيكون ممثلو الشركة متاحين لعقد اجتماعات واحد-إلى-واحد.
4D Molecular Therapeutics (纳斯达克：FDMT)表示管理层将参加在 Chardan 第9届年度遗传药物大会上的小组讨论，日期为 2025年10月21日。
管理层将出席两个小组讨论：“In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications”，时间为 美东时间上午9:30，以及 “In Vivo Gene Therapies in the Lung: Treating CF and Beyond”，时间为 美东时间下午2:00。将提供网络直播，归档版本将会在长达一年的时间内张贴在 投资者板块，地址为 https://ir.4dmoleculartherapeutics.com/events。公司代表也将提供一对一会谈。
- None.
- None.
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in panel discussions at Chardan’s 9th Annual Genetic Medicines Conference on October 21st, 2025. Members of the management team will also be available for one-on-one meetings.
Chardan’s 9th Annual Genetic Medicines Conference
| Panel Title: | In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications |
| Presentation Time: | 9:30 a.m. ET |
| Webcast Link: | Webcast |
| Panel Title | In Vivo Gene Therapies in the Lung: Treating CF and Beyond |
| Presentation Time: | 2:00 p.m. ET |
| Webcast Link: | Webcast |
Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
FAQ
When will 4DMT (FDMT) present at Chardan's 9th Annual Genetic Medicines Conference?
What panels will 4DMT (FDMT) join at the October 21, 2025 conference?
How can investors watch 4DMT (FDMT) webcasts for the October 21, 2025 panels?
Where will 4DMT (FDMT) host archived recordings of the October 21, 2025 presentations?
Will 4DMT (FDMT) management be available for meetings at Chardan's October 21, 2025 conference?
